Novigrel (Clopidogrel Besilate)

Novigrel, a P2Y12 receptor antagonist, is employed in several cardiovascular conditions to inhibit platelet aggregation.

• Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke.
• Post‑percutaneous coronary intervention (PCI): prevents stent thrombosis and recurrent ischemic events.
• Established peripheral arterial disease, recent myocardial infarction or stroke: lowers incidence of atherothrombotic events.

• Clopidogrel Besilate is a pro‑drug that, after hepatic conversion, irreversibly binds to the P2Y12 ADP receptor on platelet surfaces. This blockade prevents ADP‑mediated activation of the glycoprotein IIb/IIIa complex, thereby inhibiting platelet shape change, granule release and aggregation, which reduces thrombus formation in arterial circulation.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Bleeding: mild to moderate gastrointestinal or mucosal bleeding.
• Bruising: increased tendency to develop bruises.
• Diarrhea: loose stools, often transient.
• Nausea: mild, occasional nausea.
• Headache: intermittent headache.
• Rash: mild skin irritation.

Serious or Rare Side Effects

• Severe bleeding: intracranial hemorrhage or life‑threatening gastrointestinal bleed.
• Thrombotic thrombocytopenic purpura (TTP): rare, potentially fatal microangiopathic disorder.
• Allergic reactions: anaphylaxis or severe hypersensitivity.
• Hepatotoxicity: elevated liver enzymes in rare cases.
• Hemolytic anemia: uncommon but serious.
• Thrombocytopenia: marked reduction in platelet count.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients closely.

• Assess bleeding risk: review history of hemorrhage, ulcers or coagulopathy.
• Monitor platelet function: consider laboratory testing in high‑risk patients.
• Avoid in active pathological bleeding: contraindicated during uncontrolled bleeding episodes.
• Caution in hepatic impairment: dose adjustment may be required.
• Discontinue before surgery: stop according to procedural guidelines.
• Store at below 25°C: keep in the original pack, protect from moisture.

Clopidogrel Besilate may interact with several drug classes, influencing bleeding risk or antiplatelet efficacy.

Major Interactions (Avoid)

• Concurrent use with oral anticoagulants (e.g., warfarin): markedly increased bleeding risk.
• Combination with strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole): reduced conversion to active metabolite, diminishing antiplatelet effect.
• Use with non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened gastrointestinal bleeding.

Moderate Interactions (Monitor Closely)

• Co‑administration with proton pump inhibitors (e.g., pantoprazole): possible interaction, monitor clinical response.
• Concurrent use with selective serotonin reuptake inhibitors (SSRIs): may increase bleeding tendency, observe for signs.
• Combination with other antiplatelet agents (e.g., aspirin): additive effect on bleeding, require careful monitoring.